Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
41
Journal Issue
16
Date Issued
2023-06-01
Author(s)
Sequist, Lecia V
Yamamoto, Nobuyuki
O'Byrne, Kenneth
Hirsh, Vera
Mok, Tony
Geater, Sarayut Lucien
Orlov, Sergey
Tsai, Chun-Ming
Boyer, Michael
Su, Wu-Chou
Bennouna, Jaafar
Kato, Terufumi
Gorbunova, Vera
Lee, Ki Hyeong
Shah, Riyaz
Massey, Dan
Zazulina, Victoria
Shahidi, Mehdi
Schuler, Martin
Abstract
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
SDGs